Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Venisse

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Fundamental & Clinical Pharmacology|July 3, 2020
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatmentsNicolas Venisse
Therapie|April 7, 2011
[Level of evidence for therapeutic drug monitoring of aminoglycosides]Nicolas Venisse, Audrey Boulamery,
Therapie|July 10, 2016
[Not Available]Nicolas Venisse, Audrey Boulamery,
Therapie|June 4, 2011
[Level of evidence for therapeutic drug monitoring of fluconazole]Nicolas Venisse, Chantal Le Guellec
Therapie|July 10, 2016
[Not Available]Audrey Boulamery, Nicolas Venisse, Chantal Le Guellec, et al.
Therapie|April 7, 2011
[Level of evidence for therapeutic drug monitoring of teicoplatin]Audrey Boulamery, Nicolas Venisse, Chantal Le Guellec, et al.
The Lancet. Diabetes & Endocrinology|March 21, 2020
BPA and risk assessmentAntoine Dupuis, Sylvie Rabouan, Virginie Migeot, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2008
Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicansNicolas Venisse, Nicolas Grégoire, Manuella Marliat, et al.
The Journal of Infection|September 30, 2015
Clindamycin and rifampicin: No bull's eye without a targetGuillaume Béraud, Gwenaël Le Moal, Sophie Sury, et al.
Antimicrobial Agents and Chemotherapy|November 13, 2008
Preparation and stability of voriconazole eye drop solutionAntoine Dupuis, Nicolas Tournier, Gwenaël Le Moal, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Fundamental & Clinical Pharmacology|July 3, 2020
Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatmentsNicolas Venisse
Therapie|April 7, 2011
[Level of evidence for therapeutic drug monitoring of aminoglycosides]Nicolas Venisse, Audrey Boulamery,
Therapie|July 10, 2016
[Not Available]Nicolas Venisse, Audrey Boulamery,
Therapie|June 4, 2011
[Level of evidence for therapeutic drug monitoring of fluconazole]Nicolas Venisse, Chantal Le Guellec
Therapie|July 10, 2016
[Not Available]Audrey Boulamery, Nicolas Venisse, Chantal Le Guellec, et al.
Therapie|April 7, 2011
[Level of evidence for therapeutic drug monitoring of teicoplatin]Audrey Boulamery, Nicolas Venisse, Chantal Le Guellec, et al.
The Lancet. Diabetes & Endocrinology|March 21, 2020
BPA and risk assessmentAntoine Dupuis, Sylvie Rabouan, Virginie Migeot, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2008
Mechanism-based pharmacokinetic-pharmacodynamic models of in vitro fungistatic and fungicidal effects against Candida albicansNicolas Venisse, Nicolas Grégoire, Manuella Marliat, et al.
The Journal of Infection|September 30, 2015
Clindamycin and rifampicin: No bull's eye without a targetGuillaume Béraud, Gwenaël Le Moal, Sophie Sury, et al.
Antimicrobial Agents and Chemotherapy|November 13, 2008
Preparation and stability of voriconazole eye drop solutionAntoine Dupuis, Nicolas Tournier, Gwenaël Le Moal, et al.
Pageof 6